{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:38Z","timestamp":1753891238782,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anticoagulation is recommended for stroke prevention in patients with atrial fibrillation (AF). The guidelines suggest non-vitamin K antagonist anticoagulants (NOACs) as the primary therapy for anticoagulation in AF. Several patient-related factors increase the risk of thrombotic events: elderly individuals, a previous history of stroke, and chronic kidney disease. This study aims to determine the association between NOACs and other patient variables in AF and the occurrence of thrombotic events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The database included all adults with the code K78 (ICPC-2 code for AF) who received clinical care in Northern Portugal\u2019s Primary Health Care between January 2016 and December 2018 and were dispensed the same NOAC at the pharmacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results indicate that 10.2% of AF patients on NOAC anticoagulation experienced a stroke. Furthermore, patients treated with apixaban and dabigatran had higher odds of experiencing a stroke compared to those treated with rivaroxaban. Among patients with the same age, gender, and CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>Vasc Score, apixaban was significantly associated with a higher likelihood of thrombotic events than rivaroxaban.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results have not been previously reported in studies with real-world data; therefore, a more detailed analysis should be conducted to enhance the validity of these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1273304","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:35:48Z","timestamp":1712921748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["AF-React study: Prevalence of thrombotic events in patients with atrial fibrillation receiving NOACs \u2013 real-world data analysis from northern Portugal primary healthcare"],"prefix":"10.3389","volume":"11","author":[{"given":"Susana Silva","family":"Pinto","sequence":"first","affiliation":[]},{"given":"Andreia","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Teresa S.","family":"Henriques","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Martins","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2015.0382","article-title":"Preventing stroke in patients with atrial fibrillation\u2013a steep climb away from achieving peak performance.","volume":"1","author":"Piccini","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10557-020-06981-3","article-title":"Anticoagulants for stroke prevention in atrial fibrillation in elderly patients.","volume":"34","author":"Sch\u00e4fer","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: Relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.","volume":"43","author":"Zirlik","year":"2017","journal-title":"J Thromb Thrombolysis."},{"key":"B4","first-page":"165","article-title":"Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?","volume":"7","author":"Hanley","year":"2015","journal-title":"J Thorac Dis."},{"key":"B5","article-title":"NOACs vs. Warfarin for stroke prevention in nonvalvular atrial fibrillation.","volume":"9","author":"Patel","year":"2017","journal-title":"Cureus."},{"key":"B6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ana.25489","article-title":"Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.","volume":"85","author":"Seiffge","year":"2019","journal-title":"Ann Neurol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS).","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"B9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: A nationwide cohort study.","volume":"6","author":"Rutherford","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619898764","article-title":"A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation.","volume":"26","author":"Hill","year":"2020","journal-title":"Clin Appl Thromb."},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1160\/TH07-08-0508","article-title":"Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.","volume":"99","author":"Hughes","year":"2008","journal-title":"Thromb Haemost."},{"key":"B12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: A systematic review.","volume":"69","year":"2007","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro heart survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"B14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study.","volume":"119","author":"Go","year":"2009","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism trial in atrial fibrillation) and ATRIA (AnTicoagulation and risk factors in atrial fibrillation) study cohorts.","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022478","article-title":"Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: The prospective, multicentre observational PREvention oF thromboembolic events \u2013 European registry in atrial fibrillation (PREFER in AF).","volume":"9","author":"Rohla","year":"2019","journal-title":"BMJ Open."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040404","article-title":"AF-react study: Atrial fibrillation management strategies in clinical practice\u2013retrospective longitudinal study from realworld data in Northern Portugal.","volume":"11","author":"Silva Pinto","year":"2021","journal-title":"BMJ Open."},{"key":"B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CLEP.S290707","article-title":"Stroke incidence and death in atrial fibrillation patients newly treated with direct oral anticoagulants.","volume":"13","author":"Gabet","year":"2021","journal-title":"Clin Epidemiol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/ijs.12295","article-title":"Management of acute stroke in patients taking novel oral anticoagulants.","volume":"9","author":"Hankey","year":"2014","journal-title":"Int J Stroke."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1093\/eurheartj\/ehab315","article-title":"Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: A nationwide population-based cohort study.","volume":"42","author":"Lee","year":"2021","journal-title":"Eur Heart J."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0870-2551(12)70034-3","article-title":"Velhos e novos anticoagulantes orais. Perspetiva farmacol\u00f3gica.","volume":"31","author":"Marques Da Silva","year":"2012","journal-title":"Rev Port Cardiol."},{"key":"B23","article-title":"Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation: An instrumental variable analysis of a nationwide cohort.","volume":"13","author":"Bonde","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064662","article-title":"Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: An observational cohort study.","volume":"12","author":"Jaksa","year":"2022","journal-title":"BMJ Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1503\/cmaj.200778","article-title":"Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation.","volume":"193","author":"Reddiess","year":"2021","journal-title":"Can Med Assoc J."},{"key":"B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5853\/jos.2017.02810","article-title":"Heart failure as a risk factor for stroke.","volume":"20","author":"Kim","year":"2018","journal-title":"J Stroke."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study: Female sex and stroke risk in AF.","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B28","first-page":"385","article-title":"Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms.","volume":"111","author":"Cove","year":"2014","journal-title":"Thromb Haemost."},{"key":"B29","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/europace\/euv401","article-title":"Atrial fibrillation and risk of stroke: A nationwide cohort study.","volume":"18","author":"Christiansen","year":"2016","journal-title":"Europace."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016560","article-title":"Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant).","volume":"98","author":"Ga\u017eov\u00e1","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.15420\/usc.2016:1:1","article-title":"Identification of patients at risk of stroke from atrial fibrillation.","volume":"10","author":"Fohtung","year":"2016","journal-title":"US Cardiol Rev."},{"key":"B32","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.jacc.2018.08.1046","article-title":"CAD is an independent risk factor for stroke among patients with atrial fibrillation.","volume":"72","author":"Steensig","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0040-1716750","article-title":"Noncanonical effects of oral thrombin and factor Xa inhibitors in platelet activation and arterial thrombosis.","volume":"121","author":"Polzin","year":"2021","journal-title":"Thromb Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.10.005","article-title":"Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?","volume":"195","author":"Polzin","year":"2019","journal-title":"Pharmacol Ther."},{"key":"B35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","article-title":"Effect of hypertension on anticoagulated patients with atrial fibrillation.","volume":"28","author":"Lip","year":"2007","journal-title":"Eur Heart J."},{"key":"B36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjmed.2020.08.035","article-title":"LDL cholesterol and ischemic stroke in patients with nonvalvular atrial fibrillation.","volume":"134","author":"Omelchenko","year":"2021","journal-title":"Am J Med."},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.0472","article-title":"The association of stroke rate with low density lipoprotein and statin exposure in patients with atrial fibrillation (AF).","author":"Shweikialrefaee","year":"2021","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1273304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:35:59Z","timestamp":1712921759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1273304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":37,"alternative-id":["10.3389\/fmed.2024.1273304"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1273304","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"article-number":"1273304"}}